You are here

BeiGene

Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene

Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene

Xtalks

Flag link:

Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market

Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market

Pharmaforum

Boehringer Ingelheim

drug manufacturing

Flag link:

3 Blockbuster Cancer Drug Launches to Watch in 2020

3 Blockbuster Cancer Drug Launches to Watch in 2020

Motley Fool

Seattle Genetics

Flag link:

Corporate and regulatory developments over the Christmas period

Corporate and regulatory developments over the Christmas period

EP Vantage

Ono Pharmaceutical

Xyphos Biosciences

Flag link:

5 New Drug Approvals the FDA Gave Top Priority

5 New Drug Approvals the FDA Gave Top Priority

Motley Fool

Global Blood Therapeutics

Vertex Pharmaceuticals

Flag link:

FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates

FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates

RAPS.org

Vertex Pharmaceuticals

Global Blood Therapeutics

Flag link:

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

Yahoo/Reuters

mantle cell lymphoma

Flag link:

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Endpoints

Flag link:

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Pharmaforum

Flag link:

BeiGene's first U.S. NDA tests global development strategy

BeiGene's first U.S. NDA tests global development strategy

BioCentury

drug development

Flag link:

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

Yahoo/Motley Fool

Bristol-Myers Squibb

Flag link:

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

Endpoints

Bristol-Myers Squibb

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

Yahoo/Benzinga

Akero Therapeutics

Dermavant Sciences

Prevail Therapeutics

Stoke Therapeutics

Flag link:

Upcoming events – Crucial data on zanubrutinib and filgotinib approach

Upcoming events – Crucial data on zanubrutinib and filgotinib approach

EP Vantage

Waldenström’s macroglobulinemia

Sjögren’s syndrome

Flag link:

Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

Endpoints

Flag link:

Smaller groups await Bristol-Myers Squelgene fallout

Smaller groups await Bristol-Myers Squelgene fallout

EP Vantage

Bristol-Myers Squibb

Vividion Therapeutics

Skyhawk Therapeutics

Dragonfly Therapeutics

Agios Pharmaceuticals

Jounce Therapeutics

Flag link:

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

Endpoints

Flag link:

BMS deal weighs on Celgene partners

BMS deal weighs on Celgene partners

BioCentury

Bristol-Myers Squibb

Flag link:

BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics

BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics

Fierce Biotech

bispecific antibodies

Flag link:

Pages